Catalyst Pharmaceuticals Inc (CPRX)
Pretax margin
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 216,263 | 188,789 | 93,563 | 86,287 | 94,511 | 80,812 | 144,840 | 124,573 | 104,719 | 84,524 | 72,589 | 60,244 | 52,667 | 48,578 | 46,243 | 40,736 | 41,890 | 41,571 | 44,073 | 45,090 |
Revenue (ttm) | US$ in thousands | 491,734 | 460,482 | 434,475 | 411,347 | 398,204 | 348,393 | 302,949 | 256,480 | 214,203 | 191,755 | 170,465 | 153,717 | 140,833 | 133,539 | 126,902 | 120,142 | 119,073 | 118,181 | 119,761 | 118,994 |
Pretax margin | 43.98% | 41.00% | 21.53% | 20.98% | 23.73% | 23.20% | 47.81% | 48.57% | 48.89% | 44.08% | 42.58% | 39.19% | 37.40% | 36.38% | 36.44% | 33.91% | 35.18% | 35.18% | 36.80% | 37.89% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $216,263K ÷ $491,734K
= 43.98%
The pretax margin of Catalyst Pharmaceuticals Inc has shown fluctuations over the past few years. It started at a strong level of 37.89% in March 2020, showing the company's ability to generate profits before taxes. The margin slightly decreased to 36.80% by June 2020 but remained relatively stable throughout the rest of 2020, hovering around 35-36%.
In the first half of 2021, there was a decline in the pretax margin to 33.91% in March, followed by a recovery to 36.44% in June. The trend continued to improve in the second half of 2021, reaching 37.40% by December. The company's profitability further increased in 2022, with the pretax margin expanding to 48.89% by December.
However, the pretax margin experienced a significant drop in the first half of 2023, falling to 23.20% in September. This downward trend continued with a slight recovery to 23.73% by December 2023. The profitability rebounded in the first half of 2024, reaching 43.98% by December 2024, showcasing a remarkable improvement.
Overall, the analysis of Catalyst Pharmaceuticals Inc's pretax margin indicates considerable variability in profitability levels over different periods, demonstrating the company's ability to adapt to changing market conditions and operational challenges.
Peer comparison
Dec 31, 2024